Clinical Trial: A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07258511) titled 'A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma' on Nov. 21.

Brief Summary: The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

Study Start Date: Feb. 20, 2026

Study Type: INTERVENTIONAL

Condition: Multiple Myeloma

Intervention: DRUG: JNJ-79635322

JNJ-79635322 will be administered as SC injection.

DRUG: Teclistamab

Teclistamab will be administered as SC injection.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: ...